The blood-brain barrier (BBB) protects the brain from toxins and infectious agents by tightly regulating the passage of chemicals between the circulatory system and the brain. Not only does the BBB prevent most molecules from interacting with brain tissue, but the BBB prevents systemic drugs that could otherwise be effective from reaching the brain.
Our NeuroAccess™ medical device will enable precision medicine, the ability to deliver drugs, and measure circulating biomarkers with a blood test to diagnose and track brain diseases by reversibly opening the blood-brain barrier. We plan to develop applications for patients with brain cancers, Alzheimer's, Parkinson's, and Epilepsy. The device targets the diseased part of the brain and utilizes low-frequency focused ultrasound and microbubbles to mechanically open up the BBB.
Our device has an approved patent and multiple pending patents. The device utilizes focused ultrasound technology, which has been researched by multiple researchers worldwide. Our research makes it possible to enable the broad deployment of the focused ultrasound technology in a patient-friendly and non-invasive manner.
Coming together to impact one of the greatest healthcare challenges of our generation.
We will work closely with thought leaders and pharma in each indication to ensure we are leveraging our technology to develop the greatest value to patients and our company. We have made tremendous progress; learn more about our successes and noteworthy updates.